Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

24.48 +0.51 (+2.11%)
Streaming Delayed Price Updated: 12:52 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 235,458
Open 24.02
Bid (Size) 24.46 (1)
Ask (Size) 24.49 (3)
Prev. Close 23.97
Today's Range 23.76 - 25.08
52wk Range 13.82 - 25.95
Shares Outstanding 90,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Myriad Genetics Earns 2024 Great Place To Work® Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Key Takeaways From Myriad Genetics Analyst Ratings
Via Benzinga

Performance

YTD
+28.82%
+28.82%
1 Month
+9.51%
+9.51%
3 Month
+14.16%
+14.16%
6 Month
+28.82%
+28.82%
1 Year
+5.40%
+5.40%

More News

Read More
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics: Q4 Earnings Insights
Via Benzinga
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Via MarketBeat
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
From Myriad Genetics, Inc.
Via GlobeNewswire
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Via InvestorPlace
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
From Myriad Genetics, Inc.
Via GlobeNewswire
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
From Myriad Genetics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.